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ABSTRACT
A major challenge to successful antiviral therapy
is the emergence of drug-resistant viruses.
Recent studies have developed several automated
analyses of HIV sequence polymorphism based on
calculations of selection pressure (Ka/Ks) to pre-
dict drug resistance mutations. Similar resistance
analysis programs for HCV inhibitors are not cur-
rently available. Taking advantage of the recently
available sequence data of patient HCV samples
from a Phase II clinical study of protease inhibitor
boceprevir, we calculated the selection pressure
for all codons in the HCV protease region (amino
acid 1–181) to identify potential resistance muta-
tions. The correlation between mutations was
also calculated to evaluate linkage between any
two mutations. Using this approach, we identified
previously known major resistant mutations,
including a recently reported mutation V55A. In
addition, a novel mutation V158I was identified,
and we further confirmed its resistance to boce-
previr in protease enzyme and replicon assay. We
also extended the approach to analyze potential
interactions between individual mutations and
identified three pairs of correlated changes. Our
data suggests that selection pressure-based ana-
lysis and correlation mapping could provide
useful tools to analyze large amount of sequen-
cing data from clinical samples and to identify
new drug resistance mutations as well as their
linkage and correlations.
INTRODUCTION
More than 170 million people worldwide are chroni-
cally infected with the hepatitis C virus (HCV).
Combination therapy with pegylated interferon-alpha
plus ribavirin achieves sustained virologic response rates
of only  50% in HCV genotype 1 infected patients (1–3),
which emphasizes the need for new antiviral drugs. The
viral serine protease NS3-4A is responsible for the cleav-
age of the viral polyprotein into functional individual pro-
teins (4), and has become a promising drug target for
speciﬁc antiviral treatment. Data for clinical eﬃcacy
drug resistance have been published for several protease
inhibitors BILN-2061 (ciluprevir) (5,6), VX-950 (tela-
previr) (7,8) and SCH 503034 (boceprevir) (9). A major
challenge to successful antiviral therapy is the emergence
of drug-resistant viruses. Due to the rapid viral dynamics
and high mutation rate of HCV polymerase, large pools of
genetically distinct but closely related variants are gener-
ated in infected patients (10). During treatment, the strong
selective pressure allows the outgrowth of variants resis-
tant to therapy which can result in viral load rebound and
reduced clinical eﬃcacy.
The protease inhibitor boceprevir (SCH 503034) binds
to the enzyme active site and inhibits cleavage of the viral
polyprotein (11). It has been under clinical investigation in
mono- and combination therapy regimens. Resistance
mutations to boceprevir have been identiﬁed in the HCV
replicon system as well as in clinical trials. The resistance
loci are V36, Q41, F43, T54, R155, A156 and V170, which
are located near the inhibitor binding site (12–15).
Although the replicon system has proven to be a valu-
able tool to identify resistance mutations to protease
inhibitors, comprehensive evaluation of clinical
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development of resistance and evolution of viral popula-
tion under clinical settings. Several automated analyses of
HIV sequence polymorphism to predict drug resistance
mutations were published in the past few years (16,17).
One very widely used metric of selection pressure that
has been adapted in these studies is known as Ka/Ks
(18,19) which measures the ratio of observed non-synon-
ymous mutations over observed synonymous mutations,
normalized by the ratio expected under a neutral model.
Methods used for inferring Ka/Ks ratios are constantly
being developed (20–23). A ratio around 1 indicates
either neutral evolution or an averaging of positive and
negative selective pressures. A ratio less than 1 indicates
negative selection, with most amino-acid mutations being
deleterious. A ratio signiﬁcantly greater than 1 indicates
positive selective pressure, which is less common and sug-
gests that amino acid changes are favored, i.e. they reﬂect
a change in the function of a gene or a change in environ-
ment conditions that forces the organism to adapt, thus
increase organism’s ﬁtness.
In silico analysis of drug resistant mutation using a
selection pressure-based method in these studies has pro-
vided a valuable resource for HIV research community.
Similar studies for HCV are not currently available. In this
study, taking advantage of the recently available sequence
data of patient HCV samples from a boceprevir Phase II
clinical study, we calculated the selection pressure for all
the codons on the HCV protease region and by combining
with frequency based ﬁltering approach, we identiﬁed all
major known resistant mutations as well as novel non-
synonymous mutations that confer resistance to HCV
protease inhibitor treatment.
MATERIALS AND METHODS
Sample selections
Samples used in this study were obtained from a Phase II
clinical study of HCV protease inhibitor boceprevir
(SCH 503034) in genotype 1 non-responders. Patient
blood samples at time points speciﬁed by study protocol
were collected and HCV RNA was extracted, ampliﬁed
and sequenced. Additional samples were selected by
study clinicians based on virological response of individ-
ual patients. Because samples and protease sequences were
not available from all subjects at all time points, it was not
possible to select a single on-treatment time point for ana-
lysis. Therefore, the last on-treatment time point was used
for each subject. Samples collected from subjects prior to
boceprevir treatment were used as baseline controls.
Amplification of HCV NS3 protease region and
DNA sequencing
Viral RNA was extracted from human plasma samples
using a commercially available silica-gel membrane
based kit (QIAamp Virus BioRobot 9604 Kit, Qiagen,
Valencia, CA) and processed on an automated
BioRobot 9604 system (Qiagen). Reverse transcription
of RNA was performed using a SuperScript III First
Strand Synthesis Supermix kit (Invitrogen, Carlsbad,
CA), with random hexamers according to manufacturer’s
instructions. PCR was conducted with a Platinum PCR
SuperMix kit (Invitrogen), using 3ml cDNA, 200nM
NS3 protease gene-speciﬁc primers (forward primer: GT
AGAGCCCGTCGTCTTCTC; reverse primer: GTGCTC
TTGCCGCTGCCAGT), and 45ml of Platinum PCR
Supermix (proprietary mix contains anti-Taq DNA poly-
merase antibody, Mg
2+, dNTPs and recombinant Taq
DNA polymerase). Cycle sequencing reactions were per-
formed using a BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA), gene-speciﬁc
primer and 5–10ng of puriﬁed DNA according to manu-
facturer’s instructions. Reaction products were puriﬁed on
a Biomek FX system (Beckman Coulter, Fullerton, CA)
using a magnetic bead kit (Agencourt CleanSEQ Kit,
Agencourt Bioscience Corporation, Beverly, MA). DNA
sequencing of puriﬁed material was conducted on a 3730xl
DNA Analyzer (Applied Biosystems).
Clonal sequencing was carried out on a subset of patient
samples. Puriﬁed RT-PCR products were cloned using the
TOPO TA Cloning Kit (pCR 2.1TOPO vector,
Invitrogen). For each serum sample, 96 bacteria colonies
were sent to Qiagen or Genewiz for sequencing, using M13
forward and reverse primers as well as two protease
speciﬁc primers (56f, GACATCATCTTGGGTCTGC
CCGTCTC, 65r, GTGGGAGCGTGTAGGTGGGC).
Sequence reads were aligned with HCV template sequence
D90208 and mutations were analyzed.
Sequencing data analysis
The sequenced region included codons 1–181 of the HCV
protease NS3 region. Base calling was done using PHRED
(24). Quality scores from PHRED output were extracted
and used to select chromatograms with good quality for
subsequent analysis. For mixture positions where the
chromatogram indicated that a mixture of more than
one nucleotide was present, only the major peak was
called. For each sample, at least four sequencing reads
with good quality were required to cover each nucleotide
position and at least one of them was required to come
from a diﬀerent sequencing direction. ClustalW (25) was
used to align sequences to a template HCV sequence
(D90208). Consensus NS3 region sequences from both
before- and after-treatment samples were generated for
each subject from the ClustalW alignments and were com-
pared at each nucleotide position for each subject.
Nucleotide changes were recorded and mutation type
(transition or transversion) were determined. Amino-acid
changes before and after treatment for each codon posi-
tion were also recorded. HCV NS3 region sequences from
before and after treatment used in this study can be
obtained from GenBank (FJ830936 to FJ831439).
Ka/Ks calculation and selection pressure analysis
Amino-acid selection pressure at each codon was
calculated using the following formula developed by
Chen et al. (16,17)
Ka
Ks
¼
Na=Ns
ðna,t ft þ na,vfvÞ=ðns,tft þ ns,vfvÞ
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mutations and synonymous mutations observed at the
codon, na,t is the number of possible transition mutations
in the codon that would change the resulting amino acid,
ns,t is the number of possible transition mutations that are
synonymous, na,v and ns,v are the equivalent numbers
for transversions, and ft and fv are the transition and
transversion frequencies, respectively. ft and fv are mea-
sured using the entire dataset according to: ft=Nt/(ntS),
fv=Nv/(nvS), where S is the total number of samples,
Nt and Nv are the number of observed transition and
transversion respectively, nt is the number of possible tran-
sitions in the region that was sequenced (equal to the
length L of the sequence in nucleotides), and nv is the
number of possible transversions (equal to 2L).
An LOD conﬁdence score for a codon to be under pos-
itive selection pressure was also calculated according to
the following formula (16,17)
LOD ¼  log10
X N
i¼Na
N
i
  
qi ð1   qÞ
N i
where N is the total number of mutations observed in the
codon and q is calculated as follows:
q ¼
na,t ft þ na,vfv
3ft þ 6fv
Confirmation of boceprevir resistance of novel mutations
To generate mutant proteases carrying resistance muta-
tions, the nucleotide changes were introduced using the
QuikChange mutagenesis kit (Stratagene). The parental
plasmid expressing His-tagged single chain NS4A-
NS3 protease domain, NS4A21–32-GSGS-NS33–181, was
described by Taremi et al. (26). The expression and puri-
ﬁcation protocol was described in detail by Taremi et al.
(26). Recombinant proteases were tested using a chromo-
genic assay as described by Zhang et al. (27). The overall
inhibition constant Ki
  (where vs=VmaxS/(Km(1+1/
Ki
 ))) was used to measure inhibitor potency.
The construction and sensitivity testing of mutant
replicons have been described previously (12). The
QuikChange (Stratagene) template was plasmid pUC18
1–5, which contained the 50 half of the subgenomic repli-
con sequence (T7 promoter to EcoRI site in NS5A). The
PmeI-EcoRI fragment, which contained the coding
sequence for NS3 to the N-terminal of NS5A, was
sequenced to conﬁrm the engineered mutations and used
to replace the same region in pUC18 Bart, which con-
tained the complete subgenomic replicon sequence (28).
To measure anti-replicon activity of compounds, replicon
cells (in triplicates) were dosed with protease inhibitors
for 3 days. The replicon RNA level was measured using
real-time PCR (Taqman assay) on the ABI PRISMS
7900HT Sequence Detection System. The dCT values
(CT5B CTGAPDH) were plotted against drug concentra-
tion and ﬁtted to the sigmoid dose response model using
Graphpad PRISM software (Graphpad Software Inc.).
IC50 was the drug dose necessary to achieve dCT=1
over the projected baseline. IC90 was the drug dose neces-
sary to achieve dCT=3.2 over the baseline.
Corrleation map of selection pressure
The eﬀect of amino-acid change at one position on amino-
acid mutation at another position was also evaluated
by calculating conditional Ka/Ks. The calculation was pro-
posed by Pan et al. (17):
Ka
Ks
  
YjXa
¼
NYaXa=NYsXa
ðna,tft þ na,vfvÞ=ðns,tft þ ns,vfvÞ
where NYaXa and NYsXa are the numbers of non-
synonymous mutations and synonymous mutations at
site Y observed in the presence of non synonymous muta-
tions at site X and all other variables retain their previous
deﬁnitions. Calculation was done pairwise for all codons
within 1–181 amino acids of NS3.
The ‘conditional selection ratio’ was deﬁned as the
ratio of the conditional Ka/Ks measured in the presence
of non-synonymous mutation at X divided by the selec-
tion pressure at Y measured in the absence of any muta-
tion at X:
Ka
Ks
  
YjX
¼
Ka=Ks ðÞ YjXa
Ka=Ks ðÞ YjXo
¼
NYaXa=NYsXa
NYaXo=NYsXo
where NYaXo and NYsXo are the numbers of samples con-
taining either an nonsynonymous mutation or synony-
mous mutation at Y and no mutation at X.
To evaluate the statistical signiﬁcance of positive
conditional selection pressure, a LOD score based on the
likelihood of observing at least NYaXa samples with non-
synonymous mutations at codons Y and X, assuming
neutral selection at codon Y:
LOD ¼  log10
X N
i¼NYaXa
N
i
  
qi ð1   qÞ
N i
where N=NYaXa + NYsXa; and q is as deﬁned above.
Structural modeling
The crystal structure of boceprevir (SCH 503034) com-
plexed with the NS3/4A protease was solved in house
[PDB code 2OBO (29)]. To model the binding mode of
telaprevir (VX-950) to the NS3/4A protease, the crystal
structure of boceprevir-NS3/4A protease was used as a
template. The backbone atoms and the ketoamide posi-
tions of boceprevir served as initial coordinates upon
which the P1–P4 side chains and P1 cap of telaprevir
were built. The P4 cap was built based on the binding
mode of another ketoamide inhibitor which has the
same N-terminal cap (PDB code 1RGQ) (30). The inhib-
itor molecule was then energy minimized in the protein
environment. In addition, point mutations were also
modeled into the three-dimensional structure of the pro-
tein. InsightII molecular modeling program (Accelrys
Software Inc., San Diego, CA) was used in the modeling.
RESULTS AND DISCUSSION
During HCV antiviral therapy, viruses with drug-
resistant mutations are expected to be positively selected.
PAGE 3 OF 7 Nucleic Acids Research,2009, Vol.37, No. 10 e74To identify such positively selected amino acids, the Ka/Ks
values were calculated for each position of the HCV NS3
protease region (amino acid 1–181). A total of 252 subjects
from this HCV protease inhibitor clinical study with
sequence data from before and on treatment samples
were included in this analysis. Because the collecting
schedule of serum samples varied with individual patients,
it was diﬃcult to choose a single ﬁxed time point for all
patients. Instead, the last on-treatment time was analyzed
to maximize the time under selection pressure. For ‘mix-
ture positions’ where the chromatogram indicated more
than one nucleotide was present, only the major peak
was analyzed. Out of the Ka/Ks values for 746 diﬀerent
non-synonymous mutations in the NS3 protease, 198
amino-acid changes have Ka/Ks value >1. In order to
focus on major mutations which may have more impact
on clinical outcome and to diﬀerentiate mutations selected
speciﬁcally for drug resistance from ‘neutral drifts’, the
following criteria were built into the mutation analysis
process: (i) Low frequency non-synonymous mutations
(in <1% treated subjects) were excluded from further
analysis. (ii) Frequency diﬀerences of mutations in
before and after treatment samples were compared using
Fisher’s exact test. Mutations whose prevalence did not
increase signiﬁcantly during therapy (P>0.1) were
excluded. Table 1 listed the resulting resistant mutations
with Ka/Ks value >1 and meeting the criteria described
above. As shown in Table 1, the major known bocepre-
vir-resistant mutations (V36M, T54A/S, R155K/T,
A156S, V170A) (12,13) were correctly identiﬁed by this
analysis. V55A is a resistance mutation identiﬁed recently
by clonal sequencing analysis of a phase I clinical trial of
boceprevir, and has been shown to confer resistance to
boceprevir and telaprevir in replicons (31). Structural ana-
lysis of V55 supports observed phenotypic resistance (31).
In our study, two mutations at V55 (V55A and V55I) were
positively selected based on Ka/Ks values, although V55A
appears to be the more favored amino-acid change based
on calculated P-values. In addition, our analysis identiﬁed
a novel mutation V158I, which ﬁt all the ﬁltering criteria.
Another mutation V163L was positively selected based on
Ka/Ks value; although the P-value was greater than 0.1, it
was also included in subsequent conﬁrmation studies to
evaluate the stringency of ﬁltering criteria. The patient
population of this trial consists of approximately equal
mixture of genotype 1a and 1b subjects. Mutation
V55A/I was found in ﬁve 1a subjects, seven 1b subjects
and two subjects with unknown subtypes. Mutation V158I
was found in ﬁve 1b subjects, and mutation V163L in two
1b subjects and one 1a subject. The number of subjects is
too small to show any statistically signiﬁcant diﬀerence in
mutation distribution in genotype 1a and 1b subjects.
Mutations V55A/I, V158I and V163L mutations are
very rare among natural isolates based on the amino-
acid frequency database constructed from GenBank data
as described previously (32).
To test whether V158I and V163L confer resistance to
boceprevir, each mutation was introduced into the single-
chain genotype 1b protease (26). As shown in Table 2,
V158I conferred low level resistance (as shown by a
2.5-fold increase in inhibition constant Ki
 ) to boceprevir
but not to telaprevir, another ketoamide inhibitor under
clinical evaluation. To conﬁrm in vitro enzyme results,
mutation V158I was cloned into a genotype 1b replicon
and shown to decrease replicon sensitivity (as shown by a
 3-fold increase in replicon EC50 value) to boceprevir but
not to telaprevir (Figure 1 and Table 2). In contrast, muta-
tion V163L did not aﬀect boceprevir inhibition of the
protease in biochemical assays (Table 2). Structural ana-
lysis (Figure 2) of the NS3 protease active site showed that
V158 is part of the substrate binding pocket and is in
direct contact with the terbutyl P3 capping group of
boceprevir. Change of this residue to a slightly bulkier
Ile could interfere with boceprevir binding. Telaprevir
has a more extended interaction with the active site via
Table 1. Positively selected mutations in HCV protease region (after ﬁltering as described in the text)
Position AA_SCRN AA_Therapy Ka/Ks LOD Number of
Mutation_Therapy
Number of
Mutation_SCRN
P-value Mutation%
in Genbank
36 V M 18.27 90.47 48 0 6.0e–16 0
54 T A 4.87 30.20 15 0 4.9e–5 0
54 T S 47.15 160.07 66 1 <2.2e–16 0
155 R K 80.80 227.17 113 1 <2.2e–16 0
156 A S 19.30 49.00 15 0 4.9e-5 0
170 V A 40.92 11.95 6 0 0.03 0.39
55 V A 5.11 13.71 10 3 0.09 0
55 V I 2.19 6.76 4 1 0.37 0
158 V I 4.38 18.22 5 0 0.06 0.39
163 V L 2.24 8.76 3 0 0.25 0
P-values are the mutation frequency diﬀerences in before and after treatment samples. Mutation % in GenBank are largely based on 1b (64%) and
1a (27%) sequences.
Table 2. Enzyme and replicon resistance of newly identiﬁed resistance
mutations
Mutations Fold change over WT SD
Enzyme (Ki
 ) Replicon (EC50)
Boceprevir V158l 2.5 1.1 3.3 0.5
V163L 1 0.3 not done
Telaprevir V158l 0.5 0.2 0.9 0.1
V163L 1 0.3 not done
Averages and SD of two to four experiments are reported.
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caused by the V158I mutation. V163 is about 9A ˚ away
from the terbutyl P3 capping group of boceprevir and is
not expected to be involved in inhibitor binding.
Current research has largely focused on the impact of
single mutations on drug resistance, and the potential of
interactions among mutations has received little attention.
The impact of an individual mutation may vary depending
on other mutations present. The interactions could be
positive (synergistic), leading to higher levels of drug
resistance than would be expected from the individual
mutations alone; or negative (antagonistic), with some
mutations eﬀectively reducing the eﬀects of others.
Compensatory mutations also can increase the replication
ﬁtness of the mutant virus, increasing the apparent eﬀects
of resistance mutations. The lack of understanding of
coordinations between mutations is at least partly due to
the limitation of commonly used sequencing methods.
Clonal sequencing can provide linkage information for
multiple mutations, but the method is labor intensive
and can only be applied to relatively small number of
samples. Population sequencing is more cost eﬀective in
evaluating large number of samples, but can not evaluate
directly the linkage of mutations at diﬀerent positions.
The multiple mutations observed in a patient by popula-
tion sequencing could be linked in a single genome or
could arise from two or more individual virus strains.
Correlated mutations may occur at both short range
positions (33) and distant positions (34). Several bioinfor-
matics methods for detecting correlated mutations have
been developed over the years (35–37). One of the key
problems that all the methods share is distinguishing
signal from noise, such as those arise from evolutionary
processes related to common ancestry. In this study, to
extract correlated mutation information from population
sequencing, we calculated Ka/Ks values for mutation at
one position (Y) conditioned on the mutation on another
position (X), a method reported by Pan et al. (17). A total
of 627 pairs of amino-acid mutations show conditional
Ka/Ks values >1. Similar ﬁlters as described for single
mutations were used to reduce false positives and the
resulting amino-acid pairs were shown in Table 3. All
three pairs of double mutations have been identiﬁed by
clonal sequencing of samples from 19 patients from this
clinical study. V36M+R155K was observed in 15/19
patients, T54S+R155K in 10/19 patients (a related muta-
tion T54A+R155K in 1/19 patient), T54S+A156S in
1/19 patient (a related mutation T54A+A156S in 1/19
patient). Double mutations (e.g. V36M+R155K) have
also been observed in patient treated with telaprevir (8).
The level of resistance conferred by double mutations
is generally multiplicative or greater (13,38). For example,
double mutant V36M+155K confers 14-fold resistance to
boceprevir, while single mutants V36M and R155K confer
only 2- and 3-fold resistance, respectively (13). The mech-
anism of interaction between those mutations on drug
resistance remains to be analyzed.
In summary, ﬁve major known HCV boceprevir drug
resistance mutations were successfully identiﬁed using
the selection pressure-based method described here,
two additional mutations V55A and V158I were identiﬁed
that were previously not revealed in subjects from
this clinical study. Use of more sensitive sequencing
method and inclusion of more data set from future
studies will increase the likelihood of identifying low
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Figure 1. Inhibition of mutant replicons by protease inhibitors.
Replicon cells carrying wild-type or mutant V158I subgenomes were
treated with boceprevir (A) or telaprevir (B) for 3 days, and replicon
RNA levels were measured by Taqman assay. The relative reduction
in replicon RNA level (dCT) was plotted against compound
concentration.
PAGE 5 OF 7 Nucleic Acids Research,2009, Vol.37, No. 10 e74prevalence mutations. Although the data set included
in this study is relatively small compared to datasets
used in similar HIV studies and other frequency based
mutation detection methods have been reported for
HCV clonal sequence analysis (8,31,39), the high success
rate of our method suggests that Ka/Ks analysis and cor-
related mutation mapping combined with proper ﬁltering
mechanism described above could provide useful tools
to identify new drug resistant mutations in HCV and
shed light on potential interactions between mutations at
diﬀerent sites.
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